SANUWAVE Health to Present at the Newport Coast Securities 2014 National Sales & Equity Conference

SANUWAVE Health to Present at the Newport Coast Securities 2014 National Sales & Equity Conference  ALPHARETTA, Ga., June 10, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV) announced the Company will present at the Newport Coast Securities 2014 National Sales & Equity Conference on Friday, June 13, at the W New York Hotel in New York City.  Kevin Richardson, SANUWAVE's Chairman of the board of directors, will present a corporate overview at 11:30 AM ET on Friday, June 13, 2014.  Company management will be available for one-on-one meetings with investors participating in the conference. For those who would like to schedule an appointment with SANUWAVE's management, please contact DC Consulting by phone, (407) 792-3333, or email investorinfo@dcconsultingllc.com.  The annual Newport Coast Securities conference will feature presentations from a carefully selected group of micro-cap and small cap growth companies. The event is designed to provide investors and Newport Coast Securities advisors with a unique opportunity to gain insight into emerging growth companies and world class alternative investment opportunities. For more information, please contact conferences@ncsecurities.com, or to register go to www.regonline.com/newportcoastsecuritiesinc2014nationalsalesequityco.  About SANUWAVE Health, Inc. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE's portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body's normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE^®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand.In the U.S., dermaPACE is currently under the FDA's Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers.SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron^® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron^® and orthoPACE^® devices in Europe, Asia and Asia/Pacific.In addition, there are license/partnership opportunities for SANUWAVE's shock wave technology for non-medical uses, including energy, water, food and industrial markets.  Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company's product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company's ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.  For additional information about the Company, visit www.sanuwave.com.  CONTACT: DC Consulting, LLC          407-792-3333          investorinfo@dcconsultingllc.com                   Investor Relations          RedChip Companies, Inc.          Mike Bowdoin, Vice President          800-733-2447, ext. 110          mike@redchip.com  SANUWAVE Health, Inc. Logo  
Press spacebar to pause and continue. Press esc to stop.